Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 12/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258453 | 1.00 | TYK2 (0.51) | TYK2HTR2BTMEM97HTR6KAT2B | |
| SCHEMBL20688117 | 1.00 | TYK2 (0.51) | TYK2HTR2BTMEM97HTR6KAT2B | |
| SCHEMBL20688123 | 0.86 | TYK2 (0.45) | TYK2HTR2BTMEM97HTR6KAT2B | |
| SCHEMBL20697213 | 0.86 | TYK2 (0.45) | TYK2HTR2BTMEM97HTR6KAT2B | |
| SCHEMBL20688129 | 0.86 | TYK2 (0.45) | TYK2HTR2BTMEM97HTR6KAT2B | |
| SCHEMBL22273177 | 0.85 | TYK2 (0.44) | TYK2HTR2BTMEM97HTR6KAT2B | |
| SCHEMBL20689303 | 0.84 | TYK2 (0.48) | TYK2HTR2BTMEM97HTR6 | |
| SCHEMBL22272836 | 0.84 | TYK2 (0.49) | TYK2 | |
| SCHEMBL20687680 | 0.83 | TYK2 (0.54) | TYK2 | |
| SCHEMBL20687639 | 0.82 | TYK2 (0.48) | TYK2ADRA1AHRH1ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885HTR2B 3398/4885TMEM97 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.